- Title
- Molecular mechanisms of action of naringenin in chronic airway diseases
- Creator
- Chin, Li Hian; Hon, Chian Ming; Chellappan, Dinesh Kumar; Chellian, Jestin; Madheswaran, Thiagarajan; Zeeshan, Farrukh; Awasthi, Rajendra; Aljabali, Alaa AA.; Tambuwala, Murtaza M.; Dureja, Harish; Negi, Poonam; Kapoor, Deepak N.; Goyal, Rohit; Paudel, Keshav Raj; Satija, Saurabh; Gupta, Gaurav; Hsu, Alan; Wark, Peter; Mehta, Meenu; Wadhwa, Ridhima; Hansbro, Philip Michael; Dua, Kamal
- Relation
- European Journal of Pharmacology Vol. 879, Issue 15 July 2020, no. 173139
- Publisher Link
- http://dx.doi.org/10.1016/j.ejphar.2020.173139
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2020
- Description
- Chronic airway inflammatory diseases are characterized by persistent proinflammatory responses in the respiratory tract. Although, several treatment strategies are currently available, lifelong therapy is necessary for most of these diseases. In recent years, phytophenols, namely, flavonoids, derived from fruits and vegetables have been gaining tremendous interest and have been extensively studied due to their low toxicological profile. Naringenin is a bioflavonoid abundantly found in citrus fruits. This substance has shown notable therapeutic potential in various diseases due to its promising diverse biological activities. In this review, we have attempted to review the published studies from the available literature, discussing the molecular level mechanisms of naringenin in different experimental models of airway inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis. Current evidences have proposed that the anti-inflammatory properties of naringenin play a major role in ameliorating inflammatory disease states. In addition, naringenin also possesses several other biological properties. Despite the proposed mechanisms suggesting remarkable therapeutic benefits, the clinical use of naringenin is, however, hampered by its low solubility and bioavailability. Furthermore, this review also discusses on the studies that utilise nanocarriers as a drug delivery system to address the issue of poor solubility.
- Subject
- naringenin; chronic airway inflammatory disease; asthma; chronic obstructive pulmonary disease; lung cancer; pulmonary fibrosis; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1460986
- Identifier
- uon:46080
- Identifier
- ISSN:0014-2999
- Language
- eng
- Reviewed
- Hits: 1257
- Visitors: 1254
- Downloads: 1
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|